TY - JOUR T1 - Long time frames to detect the impact of changing COVID-19 control measures JF - medRxiv DO - 10.1101/2020.06.14.20131177 SP - 2020.06.14.20131177 AU - Jessica E Stockdale AU - Renny Doig AU - Joosung Min AU - Nicola Mulberry AU - Liangliang Wang AU - Lloyd T Elliott AU - Caroline Colijn Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131177.abstract N2 - Background Many countries have implemented population-wide interventions such as physical distancing measures, in efforts to control COVID-19. The extent and success of such measures has varied. Many jurisdictions with declines in reported COVID-19 cases are moving to relax measures, while others are continuing to intensify efforts to reduce transmission.Aim We aim to determine the time frame between a change in COVID-19 measures at the population level and the observable impact of such a change on cases.Methods We examine how long it takes for there to be a substantial difference between the cases that occur following a change in control measures and those that would have occurred at baseline. We then examine how long it takes to detect a difference, given delays and noise in reported cases. We use changes in population-level (e.g., distancing) control measures informed by data and estimates from British Columbia, Canada.Results We find that the time frames are long: it takes three weeks or more before we might expect a substantial difference in cases given a change in population-level COVID-19 control, and it takes slightly longer to detect the impacts of the change. The time frames are shorter (11-15 days) for dramatic changes in control, and they are impacted by noise and delays in the testing and reporting process, with delays reaching up to 25-40 days.Conclusion The time until a change in broad control measures has an observed impact is longer than is typically understood, and is longer than the mean incubation period (time between exposure than onset) and the often used 14 day time period. Policy makers and public health planners should consider this when assessing the impact of policy change, and efforts should be made to develop rapid, consistent real-time COVID-19 surveillance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by Genome B.C.'s COVID-19 Rapid Response Funding Initiative (project code COV-142).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work involves data that have been made publicly available by the British Columbia Centre for Disease Control, and so no IRB approval or exemption is required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data is publicly available from the British Columbia Centre for Disease Control. In addition to that, we've archived a copy of the data on a github site linked in our manuscript. ER -